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medications, to assess its impact on healthcare costs, and to
deduce areas for further research. METHODS: A systematic lit-
erature search (1990–2004) using an exhaustive list of relevant
search terms was performed to identify articles with qualitative
and quantitative data on adherence with oral anti-diabetic agents
(OAs) and insulin. Studies describing the economic impact of
non-adherence, including impact of medication co-payment on
level of adherence, were also reviewed. Electronic Medline® and
PubMed® searches along with manual review of bibliographies
were conducted in different phases for article retrieval.
RESULTS: Adequate documentation of adherence and its eco-
nomic impact was found in 51 studies. Most adherence studies
were conducted on OAs. Thirty-seven retrospective studies
showed that adherence to diabetes treatment ranged from 31%
to 90%, mostly measured by medication possession ratio, with
levels slightly lower among insulin patients. Results varied due
to a diversity of applied methodologies, where deﬁnitions of
compliance and persistence were calculated differently. Race,
multiple dosing, mode of administration, and patients’ behav-
ioral factors were signiﬁcantly associated with adherence levels.
Economic consequences of poor adherence were identiﬁed from
seven studies (ﬁve retrospective, one patient survey, and one lon-
gitudinal cohort study), which demonstrated an increase in hos-
pitalizations, premature disability, and other adverse events
resulting in higher healthcare costs. Increasing co-payments (7
retrospective studies) resulted in a decrease in taking medications
leading to increased adverse events and subsequent healthcare
costs. CONCLUSIONS: This review conﬁrms the lack of ade-
quate treatment adherence among patients with diabetes and
illustrates the considerable economic impact. More sophisticated
methods of determining medication adherence have the poten-
tial to more accurately estimate adherence rates. Research
demonstrating adherence to insulin therapies, particularly insulin
pens, and related economic consequences are lacking in the 
literature.
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OBJECTIVE: The objective of this study was to investigate the
association between pain response and health-related quality of
life (HRQoL) in patients with diabetic peripheral neuropathic
pain (DPNP). METHODS: EQ-5D data was collected at base-
line and endpoint in three large placebo controlled randomised
trials which evaluated duloxetine treatment for DPNP over a 12-
week horizon. Patients had a clinical diagnosis of pain due to
bilateral peripheral neuropathy caused by diabetes, had a mean
24-hour average pain severity score ≥ 4 on the 11 point Likert
scale (“0 = no pain” and “10 = pain as bad as you can imagine”)
and suffered from daily pain for at least 6 months. Treatment
response was based on the level of change observed in the
average pain severity score. Three levels of clinically meaningful
pain response were deﬁned: full response (≥50% change in
average pain severity), partial response (30 to 49% change
average pain severity), and no response (<30% change in average
pain severity). Utility data at the trial endpoint were pooled and
stratiﬁed into the corresponding pain response thresholds.
RESULTS: Patients had pain and utility scores measured at base-
line (n = 1139) and trial endpoints (n = 998) across the three
randomised trials. The average pain score at baseline was 5.8 ±
1.5 with a corresponding utility score of 0.58 ± 0.26. At trial
endpoint, patients in the no response to treatment category had
lower utility scores (0.61 ± 0.24) compared to patients with
either a partial response (0.70 ± 0.16) or full response (0.78 ±
0.16). In addition, a statistically signiﬁcant negative correlation
was found, indicating that increasing pain severity was strongly
associated with lower HRQoL in DPNP patients. CONCLU-
SION: Pain response had a considerable impact on HRQoL in
DPNP patients. In addition, pain severity scores were signiﬁ-
cantly associated with lower HRQoL.
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OBJECTIVE: This study aimed to estimate the health-related
quality of life (HRQL) utility score for patients with diabetes
mellitus Type 1 and Type 2 on insulin and/or oral treatment using
EQ-5D and to compare differences in HRQL for controlled and
uncontrolled patients. METHODS: We surveyed 157 patients in
a cross sectional study with treated Type 1 and Type 2 diabetes
in Sweden (age range 20–65 years). Physicians recorded demo-
graphic and treatment information, including medications for
diabetes. HRQL was measured using the EQ-5D questionnaire
and was ﬁlled in by the patients at a physician visit. We evalu-
ated the differences between groups (e.g. treatment regimes)
using GLM-models. All statistical tests were performed at the
0.05-level of signiﬁcance and were all two-sided. EQ-5D was
linked to utility weights using an algorithm that converges
ordinal ratings into a weighed composite score. RESULTS: The
mean utility score for the entire sample was 0.81 (SD 0.21) with
a median of 0.79 (min -0.18, max 1.00). Patients with Type 1
diabetes had a higher mean utility score (0.88) than patients with
Type 2 diabetes. Patients treated with a mixed regimen of oral
antidiabetics and insulin reported a lower utility score (0.76).
However, differences between treatment groups were not signif-
icant at the 5% level (p = 0.063). No signiﬁcant difference was
estimated in the health utility score for patients with controlled
diabetes according to Swedish guidelines in comparison to
uncontrolled patients. Women had signiﬁcantly lower EQ-5D
utility score than men, 0.76 and 0.85 respectively (p = 0.0217).
The utility score ranged from 0.92 in the youngest age group
(age 20–45) to 0.78 to the oldest age group (age 61–65) (p =
0.02). CONCLUSION: Type 1 diabetes patients reported a
higher HRQL than Type 2 diabetes patients. Women had signif-
icantly lower EQ-5D score than men.
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OBJECTIVE: To test the hypothesis that improved nerve func-
tion using the anti-epileptic/migraine drug topiramate would
translate to better quality of life (QOL). METHODS: Twenty
patients with diabetic peripheral neuropathy were consented and
entered into a study on topiramate. The dosage for each patient
was titrated over a six-week period from 25mg per day to 50
mg twice a day. The patients remained on 100mg a day for 12
weeks and then were tapered off the medication over an addi-
tional 4-week period. Each patient received quantitative sensory
testing, electromyography, skin blood ﬂow, skin biopsies, and
neurological examinations before and after treatment with top-
